Przejdź do zawartości
Merck

H-076

Supelco

9-Hydroxyrisperidone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Wzór empiryczny (zapis Hilla):
C23H27FN4O3
Numer CAS:
Masa cząsteczkowa:
426.48
Kod UNSPSC:
41116107
NACRES:
NA.24

klasa czystości

certified reference material

Postać

liquid

Właściwości

Snap-N-Spike®/Snap-N-Shoot®

opakowanie

ampule of 1 mL

producent / nazwa handlowa

Cerilliant®

stężenie

1.0 mg/mL in methanol

metody

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Zastosowanie

clinical testing

format

single component solution

Warunki transportu

wet ice

temp. przechowywania

−20°C

ciąg SMILES

CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCC(O)C5=N1

InChI

1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3

Klucz InChI

PMXMIIMHBWHSKN-UHFFFAOYSA-N

informacje o genach

Opis ogólny

A Snap-N-Spike® Reference Solution suitable to use in LC/MS or GC/MS applications for urine drug testing, clinical toxicology, and forensic analysis. Also known as paliperidone, 9-Hydroxyrisperidone is sold under the brand name Invega, an atypical antipsychotic used for acute and maintenance treatment of schizophrenia. The drug is also the primary metabolite of risperidone, marketed as the atypical antipsychotic Risperdal®.

Zastosowanie


  • 9-HydroxyrisperiDonesolution for in vitro research: Employed in pharmacological studies to investigate dual antipsychotic therapies in treatment-resistant conditions, enhancing the understanding of drug interactions and efficacy (Warnick et al., 2024).

  • High-purity 9-HydroxyrisperiDoneliquid for pharmacological studies: Utilized in crystallography research to assess the impact of alkyl chain length on the crystallization behavior of related compounds, providing insights into drug formulation strategies (Chen et al., 2024).

  • Buy 9-HydroxyrisperiDonesolution for receptor binding assays: Applied in the development of novel drug delivery systems such as dissolving microneedles, enhancing the administration of long-acting antipsychotic treatments (Londhe and Bhadale, 2023).

  • 9-HydroxyrisperiDoneactive metabolite for antipsychotic research: Analyzed in postmortem toxicological assessments to identify metabolites, improving forensic analysis techniques and therapeutic drug monitoring (Yamagishi et al., 2023).

  • Analytical standard 9-HydroxyrisperiDonefor biochemistry labs: Investigated in the synthesis of prodrug microcrystals for extended-release formulations, aiding in the design of more effective and patient-friendly antipsychotic medications (Xu et al., 2022).




Informacje prawne

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Risperdal is a registered trademark of Johnson & Johnson
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Hasło ostrzegawcze

Danger

Zwroty wskazujące rodzaj zagrożenia

Klasyfikacja zagrożeń

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organy docelowe

Eyes

Kod klasy składowania

3 - Flammable liquids

Klasa zagrożenia wodnego (WGK)

WGK 1

Temperatura zapłonu (°F)

49.5 °F - closed cup

Temperatura zapłonu (°C)

9.7 °C - closed cup


Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Klienci oglądali również te produkty

Slide 1 of 4

1 of 4

N Thavichachart et al.
International journal of clinical practice, 66(10), 969-975 (2012-09-22)
To examine the demographic and psychopathological characteristics of the treatment discontinuation group compared with patients who completed with paliperidone ER treatment for 6 months. A total of 984 patients meeting the DSM-IV criteria for schizophrenia who switched their antipsychotics were
Possible paliperidone-induced neuroleptic malignant syndrome: a case report.
Armağan Özdemir et al.
The Journal of neuropsychiatry and clinical neurosciences, 24(3), E22-E23 (2012-10-06)
Paliperidone as an alternative for risperidone in a case of schizophrenia with retrograde ejaculation.
Arun Kandasamy
The Journal of neuropsychiatry and clinical neurosciences, 24(3), E17-E18 (2012-10-06)
Treatment options for residual insomnia in schizophrenia.
Lone Baandrup et al.
Acta psychiatrica Scandinavica, 127(1), 81-82 (2012-10-31)
Rabbit syndrome following discontinuation of paliperidone in a patient with schizoaffective disorder.
Chih-Sung Liang et al.
Journal of clinical psychopharmacology, 32(5), 720-721 (2012-08-29)

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej